Liver fibrosis changes in HIV-HBV-coinfected patients: Clinical, biochemical and histological effect of long-term tenofovir disoproxil fumarate use

Anders Boyd, Elisabeth Lasnier, Jean Michel Molina, Caroline Lascoux-Combe, Philippe Bonnard, Patrick Miailhes, Dominique Wendum, Jean-Luc Meynard, Pierre-Marie Girard, Karine Lacombe

Research output: Contribution to journalArticleAcademicpeer-review

32 Citations (Scopus)

Abstract

Background: Data on liver fibrosis evolution in HIV-HBV-coinfected patients treated with tenofovir disoproxil fumarate (TDF) are scarce. The effect of TDF on liver fibrosis in 148 HIV-HBV-coinfected patients was prospectively evaluated using Fibrometer® scores and liver biopsies in a subset of patients. Methods: The mean change from baseline (Δ) in Fibrometer score was modelled using a generalized estimating equation. Homogeneous continuous-time Markov models were used to study risk factors for regression or progression of liver fibrosis. Results: Median follow-up of patients treated with TDF was 29.5 months (25th-75th percentile 20.9-38.1). The distribution of scored fibrosis at TDF initiation was F0-F1 n=65, F2 n=37 and F3-F4 n=46. In patients with a baseline fibrosis score of F3-F4, Fibrometer score decreased with a triphasic shape (Fibrometer Δ at 12, 24 and 36 months after TDF initiation was -0.079, -0.069 and -0.102, respectively). Despite duration on TDF, higher fibrosis scores were noted in F3-F4 patients with high HBV viral load and HDV coinfection, and in F0-F2 patients who had high HBV viral load and low CD4 + T-cell count. Progression in fibrosis score over time was influenced by age, alcohol consumption, low CD4+ T-cell count and HCV coinfection, whereas HDV coinfection and longer duration of HBV infection prevented fibrosis regression. No influence of antiretrovirals other than TDF was found. Conclusions: The use of TDF in HIV-HBV-coinfected patients led to a decrease in liver fibrosis score in patients with advanced fibrosis or cirrhosis. Sustainability of its direct antiviral and indirect antifibrotic effects on the liver need to be studied further. ©2010 International Medical Press.
Original languageEnglish
Pages (from-to)963-974
Number of pages12
JournalAntiviral therapy
Volume15
Issue number7
DOIs
Publication statusPublished - 2010
Externally publishedYes

Keywords

  • Adenine/analogs & derivatives
  • Adult
  • Anti-HIV Agents/metabolism
  • Antiretroviral Therapy, Highly Active
  • CD4 Lymphocyte Count
  • Cohort Studies
  • DNA, Viral/drug effects
  • Female
  • HIV Infections/complications
  • Hepacivirus/drug effects
  • Hepatitis B virus/drug effects
  • Hepatitis B, Chronic/complications
  • Hepatitis C/complications
  • Hepatitis D, Chronic/complications
  • Humans
  • Liver Cirrhosis/drug therapy
  • Male
  • Middle Aged
  • Organophosphonates/metabolism
  • Tenofovir
  • Viral Load

Cite this